Patterns of Genomic Loss of Heterozygosity Predict Homologous Recombination Repair Defects in Epithelial Ovarian Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2012 Oct 11

PMID 23047548

Citations 390

Authors

V Abkevich

K M Timms

B T Hennessy

J Potter

M S Carey

L A Meyer

K Smith-McCune

R Broaddus

K H Lu

J Chen

T V Tran

D Williams

D Iliev

S Jammulapati

L M FitzGerald

T Krivak

J A Deloia

A Gutin

G B Mills

J S Lanchbury

Affiliations

Soon will be listed here.

Abstract

Background: Defects in BRCA1, BRCA2, and other members of the homologous recombination pathway have potential therapeutic relevance when used to support agents that introduce or exploit double-stranded DNA breaks. This study examines the association between homologous recombination defects and genomic patterns of loss of heterozygosity (LOH).

Methods: Ovarian tumours from two independent data sets were characterised for defects in BRCA1, BRCA2, and RAD51C, and LOH profiles were generated. Publically available data were downloaded for a third independent data set. The same analyses were performed on 57 cancer cell lines.

Results: Loss of heterozygosity regions of intermediate size were observed more frequently in tumours with defective BRCA1 or BRCA2 (P=10(-11)). The homologous recombination deficiency (HRD) score was defined as the number of these regions observed in a tumour sample. The association between HRD score and BRCA deficiency was validated in two independent ovarian cancer data sets (P=10(-5) and 10(-29)), and identified breast and pancreatic cell lines with BRCA defects.

Conclusion: The HRD score appears capable of detecting homologous recombination defects regardless of aetiology or mechanism. This score could facilitate the use of PARP inhibitors and platinum in breast, ovarian, and other cancers.

Citing Articles

Predictive biomarkers for the efficacy of PARP inhibitors in ovarian cancer: an updated systematic review.

Wang Y, Allen I, Funingana G, Tischkowitz M, Joko-Fru Y BJC Rep. 2025; 3(1):14.

PMID: 40069561 PMC: 11897386. DOI: 10.1038/s44276-025-00122-9.

Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics.

Witz A, Dardare J, Betz M, Michel C, Husson M, Gilson P Biomark Res. 2025; 13(1):31.

PMID: 39985088 PMC: 11846297. DOI: 10.1186/s40364-025-00740-y.

The American Joint Committee on Cancer (AJCC) Breast Cancer Staging, Eighth Edition, is more Reflective of Cancer Biology than the Seventh Edition.

Young J, Asaoka M, Ghasemi F, Chida K, Roy A, Yan L Ann Surg Oncol. 2025; .

PMID: 39918749 DOI: 10.1245/s10434-025-16889-7.

Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence.

Arce-Gallego S, Cresta Morgado P, Delgado-Serrano L, Simonetti S, Gonzalez M, Romero-Lozano P Cell Rep Med. 2025; 6(2):101937.

PMID: 39914385 PMC: 11866514. DOI: 10.1016/j.xcrm.2025.101937.

Whole exome sequencing-based homologous recombination deficiency test for epithelial ovarian cancer.

Chiang Y, Huang H, Kuo K, Hwu W, Lin P J Ovarian Res. 2025; 18(1):19.

PMID: 39885596 PMC: 11780812. DOI: 10.1186/s13048-024-01565-3.

References

Norquist B, Wurz K, Pennil C, Garcia R, Gross J, Sakai W . Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol. 2011; 29(22):3008-15. PMC: 3157963. DOI: 10.1200/JCO.2010.34.2980. View

Dann R, DeLoia J, Timms K, Zorn K, Potter J, Flake 2nd D . BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol. 2012; 125(3):677-82. DOI: 10.1016/j.ygyno.2012.03.006. View

Farmer H, McCabe N, Lord C, Tutt A, Johnson D, Richardson T . Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434(7035):917-21. DOI: 10.1038/nature03445. View

Wilcox C, Baysal B, Gallion H, Strange M, DeLoia J . High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors. Cancer Genet Cytogenet. 2005; 159(2):114-22. DOI: 10.1016/j.cancergencyto.2004.12.017. View

Friedenson B . BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. MedGenMed. 2005; 7(2):60. PMC: 1681605. View

Edwards S, Brough R, Lord C, Natrajan R, Vatcheva R, Levine D . Resistance to therapy caused by intragenic deletion in BRCA2. Nature. 2008; 451(7182):1111-5. DOI: 10.1038/nature06548. View

Birkbak N, Wang Z, Kim J, Eklund A, Li Q, Tian R . Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov. 2012; 2(4):366-375. PMC: 3806629. DOI: 10.1158/2159-8290.CD-11-0206. View

Sakai W, Swisher E, Jacquemont C, Chandramohan K, Couch F, Langdon S . Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res. 2009; 69(16):6381-6. PMC: 2754824. DOI: 10.1158/0008-5472.CAN-09-1178. View

Tan D, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S . "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol. 2008; 26(34):5530-6. DOI: 10.1200/JCO.2008.16.1703. View

10.

Narayan G, Arias-Pulido H, Koul S, Vargas H, Zhang F, Villella J . Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol Cancer. 2003; 2:24. PMC: 156646. DOI: 10.1186/1476-4598-2-24. View

11.

Marsit C, Liu M, Nelson H, Posner M, Suzuki M, Kelsey K . Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene. 2003; 23(4):1000-4. DOI: 10.1038/sj.onc.1207256. View

12.

Stefansson O, Jonasson J, Johannsson O, Olafsdottir K, Steinarsdottir M, Valgeirsdottir S . Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. Breast Cancer Res. 2009; 11(4):R47. PMC: 2750106. DOI: 10.1186/bcr2334. View

13.

. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15. PMC: 3163504. DOI: 10.1038/nature10166. View

14.

Venkitaraman A . Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002; 108(2):171-82. DOI: 10.1016/s0092-8674(02)00615-3. View

15.

Hennessy B, Timms K, Carey M, Gutin A, Meyer L, Flake 2nd D . Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol. 2010; 28(22):3570-6. PMC: 2917312. DOI: 10.1200/JCO.2009.27.2997. View

16.

Gelmon K, Tischkowitz M, MacKay H, Swenerton K, Robidoux A, Tonkin K . Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011; 12(9):852-61. DOI: 10.1016/S1470-2045(11)70214-5. View

17.

Holstege H, Horlings H, Velds A, Langerod A, Borresen-Dale A, van de Vijver M . BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations. BMC Cancer. 2010; 10:654. PMC: 3002929. DOI: 10.1186/1471-2407-10-654. View

18.

Bryant H, Schultz N, Thomas H, Parker K, Flower D, Lopez E . Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005; 434(7035):913-7. DOI: 10.1038/nature03443. View

19.

Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D . Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet. 2010; 42(5):410-4. DOI: 10.1038/ng.569. View

20.

OShaughnessy J, Osborne C, Pippen J, Yoffe M, Patt D, Rocha C . Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 2011; 364(3):205-14. DOI: 10.1056/NEJMoa1011418. View